Vascular endothelial growth factor - A increases the aqueous humor outflow facility

PLoS ONE

Volumn 11, Issue 9, 2016, Pages

  Fujimoto, Tomokazu ^a   Inoue, Toshihiro ^a   Maki, Kei ^a   Inoue Mochita, Miyuki ^a   Tanihara, Hidenobu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROPILIN 1; NEUROPILIN 2; PROTEIN ZO1; RECOMBINANT VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ANTERIOR EYE SEGMENT; AQUEOUS HUMOR OUTFLOW; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL SHAPE; CONTROLLED STUDY; ELECTRIC RESISTANCE; EXTRACELLULAR MATRIX; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; INTRAOCULAR PRESSURE; MACACA FASCICULARIS; MEMBRANE PERMEABILITY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHLEMM CANAL; TRABECULAR MESHWORK; ANIMAL; AQUEOUS HUMOR; CELL CULTURE; METABOLISM; PHYSIOLOGY;

ANIMALS; AQUEOUS HUMOR; CELLS, CULTURED; MACACA FASCICULARIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84990864890     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0161332     Document Type: Article

References (27)

1. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J. 2011; 437(2):169-83. doi: 10.1042/BJ20110301 PMID: 21711246.
2. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007; 6(4):273-86. doi: 10.1038/nrd2115 PMID: 17396134.
3. Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, et al. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology. 2009; 116(12):2393-9. doi: 10.1016/j.ophtha.2009.05.039 PMID: 19815292.
4. Ba J, Peng RS, Xu D, Li YH, Shi H, Wang Q, et al. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Drug Des DevelTher. 2015; 9:5397-405. doi: 10.2147/DDDT.S86269 PMID: 26451092; PubMed Central PMCID: PMCPMC4592052.
5. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012; 119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006 PMID: 23084240.
6. Group CR, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizu-mab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364(20):1897-908. doi: 10.1056/NEJMoa1102673 PMID: 21526923; PubMed Central PMCID: PMCPMC3157322.
7. Mathalone N, Arodi-Golan A, Sar S, Wolfson Y, Shalem M, Lavi I, et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2012; 250(10):1435-40. doi: 10.1007/s00417-012-1981-0 PMID: 22434210.
8. Tseng JJ, Vance SK, Della Torre KE, Mendonca LS, Cooney MJ, Klancnik JM, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma. 2012; 21(4):241-7. doi: 10.1097/IJG.0b013e31820d7d19 PMID: 21423038.
9. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. JOcul Pharmacol Ther. 2010; 26(1):105-10. doi: 10.1089/jop.2009.0076 PMID: 20187807.
10. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011; 95(8):1111-4. doi: 10.1136/bjo.2010.180729 PMID: 20702430.
11. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90(3):262-7. doi: 10.1136/bjo.2005.081224 PMID: 16488940; PubMed Central PMCID: PMCPMC1856963.
12. Tan JC, Peters DM, Kaufman PL. Recent developments in understanding the pathophysiology of elevated intraocular pressure. Curr Opin Ophthalmol. 2006; 17(2):168-74. PMID: 16552252.
13. Rohen JW. Why is intraocular pressure elevated in chronic simple glaucoma? Anatomical considerations. Ophthalmology. 1983; 90(7):758-65. PMID: 6413918.
14. Alvarado J, Murphy C, Juster R. Trabecular meshworkcellularity in primary open-angle glaucoma and nonglaucomatous normals. Ophthalmology. 1984; 91(6):564-79. PMID: 6462622.
15. Alvarado JA, Yun AJ, Murphy CG. Juxtacanalicular tissue in primary open angle glaucoma and in nonglaucomatous normals. Arch Ophthalmol. 1986; 104(10):1517-28. PMID: 3767685.
16. Inoue T, Kawaji T, Inatani M, Kameda T, Yoshimura N, Tanihara H. Simultaneous increases in multiple proinflammatory cytokines in the aqueous humor in pseudophakic glaucomatous eyes. J Cataract Refract Surg. 2012; 38(8):1389-97. doi: 10.1016/j.jcrs.2012.04.028 PMID: 22814044.
17. Sohn HJ, Han DH, Kim IT, Oh IK, Kim KH, Lee DY, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011; 152(4):686-94. doi: 10.1016/j.ajo.2011.03.033 PMID: 21782151.
18. Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, Zlabinger GJ, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci. 2009; 50(3):1025-32. doi: 10.1167/iovs.08-2510 PMID: 19060280.
19. Syriani E, Cuesto G, Abad E, Pelaez T, Gual A, Pintor J, et al. Effects of platelet-derived growth factor on aqueous humor dynamics. Invest Ophthalmol Vis Sci. 2009; 50(8):3833-9. doi: 10.1167/iovs.08-2924 PMID: 19357356.
20. Tsuboi N, Inoue T, Kawai M, Inoue-Mochita M, Fujimoto T, Awai-Kasaoka N, et al. The effect of monocyte chemoattractant protein-1/CC chemokine ligand 2 on aqueous humor outflow facility. Invest Ophthalmol Vis Sci. 2012; 53(10):6702-7. doi: 10.1167/iovs.12-10376 PMID: 22956618.
21. Ohira S, Inoue T, Shobayashi K, Iwao K, Fukushima M, Tanihara H. Simultaneous increase in multiple proinflammatory cytokines in the aqueous humor in neovascular glaucoma with and without intravitreal bevacizumab injection. Invest Ophthalmol Vis Sci. 2015; 56(6):3541-8. doi: 10.1167/iovs.14-15918 PMID: 26030108.
22. Fujimoto T, Inoue T, Kameda T, Kasaoka N, Inoue-Mochita M, Tsuboi N, et al. Involvement of RhoA/Rho-associated kinase signal transduction pathway in dexamethasone-induced alterations in aqueous outflow. Invest Ophthalmol Vis Sci. 2012;53(11):7097-108. doi: 10.1167/iovs.12-9989 PMID: 22969074.
23. Kameda T, Inoue T, Inatani M, Fujimoto T, Honjo M, Kasaoka N, et al. The effect of Rho-associated protein kinase inhibitor on monkey Schlemm's canal endothelial cells. Invest Ophthalmol Vis Sci. 2012; 53(6):3092-103. Epub 2012/04/12. iovs.11-8018 [pii] doi: 10.1167/iovs.11-8018 PMID: 22491412.
24. Honjo M, Tanihara H, Inatani M, Kido N, Sawamura T, Yue BY, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001; 42(1):137-44. Epub 2001/01/03. PMID: 11133858.
25. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). Retina. 2007; 27(8):1044-7. doi: 10.1097/IAE.0b013e3180592ba6 PMID: 18040242.
26. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008; 146(6):930-4.e1. doi: 10.1016/j.ajo.2008.07.007 PMID: 18775528.
27. Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P. Short-term effect of intravitreal injection of Ranibizumab (Lucentis)on intraocular pressure. J Glaucoma. 2009; 18(9):658-61. doi: 10.1097/IJG.0b013e31819c4893 PMID: 20010243.